Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional Study to Further Characterize the Safety and Effectiveness of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China in a Real World Setting

NCT05546125 is registered in ClinicalTrials.gov with Pfizer Pharmaceuticals Ltd. as lead sponsor.

NCT NCT05546125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05546125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional Study to Further Characterize the Safety and Effectiveness of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China in a Real World Setting
Lead sponsor
Pfizer Pharmaceuticals Ltd.
Phase
Observational
Overall status
Completed
Start date
December 23, 2021
Completion date
February 27, 2023
Enrollment
100 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension (pah)